ライフサイエンスコーパス: fluoroquinolone

1 ed linezolid, clofazimine, cycloserine and a fluoroquinolone.

2 he only available anionic (non-zwitterionic) fluoroquinolone.

3 LL and the first to include a broad-spectrum fluoroquinolone.

4 d linezolid, clofazimine, cycloserine, and a fluoroquinolone.

5 tients, including individuals resistant to a fluoroquinolone.

6 on were offered 6 months of treatment with a fluoroquinolone.

7 ntial AEs that have been observed with other fluoroquinolones.

8 increased risk of AEs associated with other fluoroquinolones.

9 her antibiotics, including the gyrase-acting fluoroquinolones.

10 to several key antimicrobials, including the fluoroquinolones.

11 MRSA infections distinguishes it from other fluoroquinolones.

12 are and convenient to use for the extraction fluoroquinolones.

13 solates were resistant to cephalosporins and fluoroquinolones.

14 h and without resistance to early-generation fluoroquinolones.

15 and no target-mediated cross-resistance with fluoroquinolones.

16 al pathogens, including strains resistant to fluoroquinolones.

17 d during treatment or acquired resistance to fluoroquinolones.

18 o beta-lactam antimicrobials, macrolides, or fluoroquinolones.

19 ly receiving intravenous vs oral respiratory fluoroquinolones.

20 2016, driven by decreases in macrolides and fluoroquinolones.

21 o third generation cephalosporins (3G-C) and fluoroquinolones.

22 orbent was developed and employed to extract fluoroquinolones.

23 fferentiate its AE profile compared to other fluoroquinolones.

24 i clone-sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (

25 OADs were aminoglycosides (43 patients) and fluoroquinolones (20 patients).

26 The most prescribed antibiotics were fluoroquinolones (35%), followed by carbapenems (20%), T

27 s associated with fewer patients receiving a fluoroquinolone (37.1% vs 48.2%; P = .01) and fewer fluo

28 raemia per 1,000 bacteraemia per quarter for fluoroquinolones; -48.3% (-62.7 to -32.3) and -153.1 (-2

29 tibiotics families: sulfonamides (9 SDs) and fluoroquinolones (6 FQs).

30 Thirty-six of 39 patients (92.3%) received a fluoroquinolone (92.3%) and 30 of 39 (76.7%) received to

31 s in rpoB were excluded), 96.2% and 100% for fluoroquinolones, 92.6% and 100% for kanamycin, 93.9% an

32 (45 [9%] vs 18 [24%], adjusted p=0.002) and fluoroquinolones (95 [19%] vs 23 [30%], adjusted p=0.017

33 e/DNA interactions is a major determinant of fluoroquinolone activity and that moieties that have bee

34 effectiveness, regimen robustness to loss of fluoroquinolone activity, and prevalence of both moxiflo

35 e or treated only with an earlier-generation fluoroquinolone (adjusted hazard ratio, 0.46 [95% confid

36 ality cost of about US$1,500 per kilogram of fluoroquinolones administered in US broiler chicken prod

37 nt was more likely to have been changed to a fluoroquinolone after presentation.

38 aluate the effectiveness of later-generation fluoroquinolones among patients with and without resista

39 prevalence of resistance to pyrazinamide and fluoroquinolones among patients with Hr-TB provides furt

40 ar spread by Bp and/or Bm Among these were a fluoroquinolone analog, which we named burkfloxacin (BFX

41 he database, 843,854 individuals receiving a fluoroquinolone and 3,543,797 patients receiving a beta-

42 ltidrug resistance with resistance to both a fluoroquinolone and a second-line injectable (XDR).

43 esistance (XDR) (MDR plus non-susceptible to fluoroquinolone and any 3rd generation cephalosporins),

44 (XDR-TB) are also resistant to all types of fluoroquinolone and at least one of the three injectable

45 National fluoroquinolone and cephalosporin prescribing correlated

46 sa cultures with a combination of commercial fluoroquinolone and our isoindoline analogs results in s

47 eptibility to early- versus later-generation fluoroquinolones and about the role of mutation-mutation

48 sistant tuberculosis that was susceptible to fluoroquinolones and aminoglycosides, a short regimen wa

49 la isolates in our study were susceptible to fluoroquinolones and aminoglycosides.

50 sistant tuberculosis that was susceptible to fluoroquinolones and aminoglycosides.

51 have implicated an association between oral fluoroquinolones and an increased risk of uveitis.

52 older than 65 years, and primary-case use of fluoroquinolones and clindamycin exceeding total use thr

53 to an increased prevalence of resistance to fluoroquinolones and extended-spectrum cephalosporins in

54 s these regimens omit isoniazid, rifampicin, fluoroquinolones and injectable aminoglycosides, they wo

55 Antibiotic resistance, particularly to fluoroquinolones and macrolides, in the major foodborne

56 l type IIA topoisomerase inhibitors, such as fluoroquinolones and novel bacterial topoisomerase inhib

57 They are not cross-resistant to fluoroquinolones and other DNA gyrase/topoisomerase IV i

58 nly 44.7% (596) had second-line DST for both fluoroquinolones and second-line injectable: 55.8% (466

59 (XDR), resistant to first-line antibiotics, fluoroquinolones and third generation cephalosporin.

60 been used to support plague indications for fluoroquinolones and to test the efficacy of additional

61 nosis of resistance to other drugs, (notably fluoroquinolones), and detection of resistance by target

62 in katG, ethA (ethionamide), gyrA and gyrB (fluoroquinolones), and pncA.

63 ion models with country-level cephalosporin, fluoroquinolone, and macrolide consumption (standard dos

64 ide but with high prevalence of beta-lactam, fluoroquinolone, and tetracycline resistance genes exist

65 cs, including beta-lactams, aminoglycosides, fluoroquinolones, and polymyxins.

66 s of antimicrobials including tetracyclines, fluoroquinolones, and sulfonamides are effective for pla

67 ologic level, reductions in total AU, use of fluoroquinolones, and use of third- and fourth-generatio

68 -generation cephalosporin], ciprofloxacin [a fluoroquinolone], and gentamicin [an aminoglycoside]).

69 ebsiella pneumoniae increases sensitivity to fluoroquinolones; antibacterials that kill cells by inhi

70 We report that the fluoroquinolone antibiotic ciprofloxacin (cipro) induces

71 osed to sub-inhibitory concentrations of the fluoroquinolone antibiotic norfloxacin.

72 ribe the rapid quantitative determination of fluoroquinolone antibiotics in poultry egg samples using

73 s infrared (DRS-FTIR) spectral monitoring of fluoroquinolone antibiotics such as ciprofloxacin (CIP)

74 cin, representative of an important class of fluoroquinolone antibiotics, has been considered to be o

75 ng and resistance to rifampin, isoniazid and fluoroquinolone antibiotics.

76 comparable antimicrobial efficacy to that of fluoroquinolone antibiotics.

77 Resistance to fluoroquinolone antimicrobial agents, particularly cipro

78 d Laboratory Standards Institute revised the fluoroquinolone antimicrobial susceptibility testing bre

79 esistant TonB mutants are cross-resistant to fluoroquinolone antimicrobials and a siderophore-conjuga

80 Ciprofloxacin and levofloxacin, 2 fluoroquinolone antimicrobials, are >=90% effective for

81 Fluoroquinolones appear to reduce these infections by in

82 Manual chart reviews to assess fluoroquinolone appropriateness at hospital discharge (i

83 Manual chart reviews to assess fluoroquinolone appropriateness at hospital discharge (i

84 Fluoroquinolones are broad-spectrum antibacterials that

85 Despite increasing awareness of harms, fluoroquinolones are still frequently prescribed to inpa

86 Adverse events (AEs) associated with the fluoroquinolones are well defined and a prospective part

87 Since antimicrobials, specifically fluoroquinolones, are one of the only routinely used con

88 We have used HCV NS3 helicase and fluoroquinolones as a model for drug-protein interaction

89 earch is needed to determine the efficacy of fluoroquinolones as monotherapy.

90 Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral fo

91 s with liver cirrhosis and an indication for fluoroquinolone-based prophylaxis of SBP.

92 ies have demonstrated the effectiveness of a fluoroquinolone-based regimen to treat individuals presu

93 We evaluated the effectiveness of fluoroquinolone-based SBP prophylaxis in an era and area

94 Fluoroquinolone-based treatment for contacts with presum

95 g most of those resistant to cephalosporins, fluoroquinolones, beta-lactam/beta-lactamase inhibitors,

96 rate constants for transformation of the six fluoroquinolones by direct photolysis at 253.7 nm were d

97 Molecular markers conferring resistance to fluoroquinolones (cdeA and gyrA) and to sulfonamides (fo

98 tion in 2009 and primary care prescribing of fluoroquinolones, cephalosporins, and co-amoxiclav and r

99 rs, aggregate (inpatient and post-discharge) fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxac

100 rvention limiting the use of 4C antibiotics (fluoroquinolones, clindamycin, co-amoxiclav, and cephalo

101 aluate the association between neighbourhood fluoroquinolone consumption and individual risk of colon

102 Fluoroquinolone consumption was positively associated wi

103 The disappointing recent failure of fluoroquinolone-containing regimens to shorten the durat

104 chemiluminescence determination of the total fluoroquinolones content using a multi-pumping flow syst

105 e intrinsically low susceptibility of Mtb to fluoroquinolones correlates with a reduction in contacts

106 l suffer from the fact that beta-lactams and fluoroquinolones coselect resistance to these novel and

107 These findings show that fluoroquinolones damage DNA in persisters and that the e

108 Overall, there were 1,727,478 fluoroquinolone days of therapy (DOTs) with 674,918 (39.

109 Overall, there were 1 727 478 fluoroquinolone days of therapy (DOTs), with 674 918 (39

110 Increasing MICs of fluoroquinolones, diabetes, and age >40 years were signi

111 ely, our data indicate that the stability of fluoroquinolone/DNA interactions is a major determinant

112 n this retrospective cohort, the majority of fluoroquinolone DOTs occurred after hospital discharge.

113 rapidly and accurately predict resistance to fluoroquinolone drugs and especially later-generation ag

114 of action shared with the highly successful fluoroquinolone drugs.

115 Cost-effectiveness was greatest using a fluoroquinolone/ethambutol combination regimen.

116 optimal antibiotic treatment included: prior fluoroquinolone exposure (adjusted odds ratio [aOR] 1.38

117 Notably, fluoroquinolone exposure appeared protective (OR 0.6, 95

118 Experimental evolution reveals that under fluoroquinolone exposure in vitro, resistant S. sonnei d

119 ong the 9 reviewed hospitals, post-discharge fluoroquinolone exposure was lower at hospitals using RP

120 mong the 9 reviewed hospitals, postdischarge fluoroquinolone exposure was lower at hospitals using RP

121 To limit aggregate fluoroquinolone exposure, stewardship programs should ta

122 ption and electron transfer reactions of two fluoroquinolones, flumequine (FLU), and norfloxacin (NOR

123 lth ministries in South Asia still recommend fluoroquinolones for enteric fever.

124 and any 3rd generation cephalosporins), and fluoroquinolone (FQ) and azithromycin non-susceptibility

125 genes responsible for resistance to INH, the fluoroquinolone (FQ) drugs, amikacin (AMK), and kanamyci

126 re consistent with existing understanding of fluoroquinolone (FQ) resistance due to mutations in the

127 gnostics that rapidly and accurately predict fluoroquinolone (FQ) resistance promise to improve treat

128 Early fluoroquinolone (FQ) use was defined as receiving >/=5 d

129 of 100 000 adults with TB receiving a novel, fluoroquinolone (FQ)-containing regimen.

130 of 100,000 adults with TB receiving a novel, fluoroquinolone (FQ)-containing regimen.

131 Resistance to azithromycin (AZM), to fluoroquinolones (FQ) and to doxycycline were investigat

132 Three fluoroquinolones (FQs) are commonly prescribed as part o

133 Recent studies have linked fluoroquinolones (FQs) to cardiac adverse events, includ

134 uggesting that removal of a later-generation fluoroquinolone from a treatment regimen because of demo

135 -Fe(3)O(4) adsorbent was utilized to extract fluoroquinolones from honey, milk and egg samples and sa

136 ed as an efficient sorbent for separation of fluoroquinolones from sample matrix.

137 ept for the last trial with ceftriaxone, the fluoroquinolone gatifloxacin was associated with equival

138 Resistance to fluoroquinolones, gentamicin, and tobramycin was seen in

139 frequent hospital admissions, greater use of fluoroquinolones, glycopeptides, cephalosporins and othe

140 isolates were high for amikacin (59.2%) and fluoroquinolones (>97%).

141 f an associated magnesium ion, which bridges fluoroquinolone-gyrase interactions.

142 participants treated with a later-generation fluoroquinolone had half the risk of mortality compared

143 Fluoroquinolones have been in clinical use for over 50 y

144 Fluoroquinolones have been used in treatment of >30% of

145 Fluoroquinolones have equivalent oral and intravenous bi

146 mum inhibitory concentrations (MICs) against fluoroquinolones have risen significantly since 2005 and

147 However, not all fluoroquinolones have the same AE profile with different

148 methoprim-sulfamethoxazole (TMP-SMZ) and the fluoroquinolones have traditionally been considered the

149 ed chemiluminescence method for screening of fluoroquinolones in milk samples was proposed.

150 e and cost-effective point-of-need screening fluoroquinolones in milk samples.

151 Patients treated with fluoroquinolones in our study had comparable outcomes to

152 (IRR 9.7; 95% CI [3.3, 35.0]; p<0.001), and fluoroquinolones in SOT (IRR 2.9; 95% CI [2.1, 4.0]; p<0

153 (IRR, 9.7 [95% CI, 3.3-35.0]; P < .001), and fluoroquinolones in SOT (IRR, 2.9 [95% CI, 2.1-4.0]; P <

154 Sensitivity to fluoroquinolones included 22 of 52 (42%) to levofloxacin

155 Fluoroquinolones increase the risk of Clostridioides dif

156 Fluoroquinolone-induced peripheral neuropathies and tend

157 HCV NS3 of genotype 1a, 1b, 2b and 3a on NS3-fluoroquinolone interaction.

158 (beta-lactams, tetracyclines, sulfonamides, fluoroquinolones, macrolides, and coccidiostats) were mo

159 ubstantially improve survival of plague, and fluoroquinolones may be equally as effective, yet lack s

160 studies suggest that use of later-generation fluoroquinolones may reduce mortality risk and improve t

161 nstrated resistance to an earlier-generation fluoroquinolone might increase mortality risk.

162 tructure-activity relationship attributes of fluoroquinolones, molecule development has improved effi

163 lactam plus macrolide combination therapy or fluoroquinolone monotherapy initiated within 4 to 8 hour

164 ess the association between later-generation fluoroquinolone (moxifloxacin or levofloxacin) use and p

165 322 [42%]), tetracycline (n = 171 [22%]), or fluoroquinolone (n = 61 [8%]), fatality was 23%, 10%, an

166 Fluoroquinolone nonsusceptibility was more common among

167 MDR and fluoroquinolone-nonsusceptible isolates were more common

168 ntimicrobial susceptibility, 1216 (61%) were fluoroquinolone-nonsusceptible, of which 272 (22%) were

169 ce and treatment regimen, including use of a fluoroquinolone, on clinical outcomes.

170 the combination of an antibiotic, usually a fluoroquinolone or azithromycin, and loperamide for rapi

171 CI, .47-.96]); ACHs with a >=20% decrease in fluoroquinolone or third- and fourth-generation cephalos

172 ith participants either not treated with any fluoroquinolone or treated only with an earlier-generati

173 ng-regimen group, and acquired resistance to fluoroquinolones or aminoglycosides occurred in 3.3% and

174 tion of mutations associated with high-level fluoroquinolone (OR, 3.99 [95% CI, 1.10 to 14.40]) and k

175 olates phenotypically resistant to rifampin, fluoroquinolones, or aminoglycosides, but for which Sang

176 stly not EPE (trimethoprim-sulfamethoxazole, fluoroquinolones, oral cephalosporins, and penicillins w

177 of acridine dye, cephalosporin, cephamycin, fluoroquinolone, penam, peptide antibiotics and tetracyc

178 Further, populations derived from fluoroquinolone persisters contain significantly greater

179 o contrast the volume and appropriateness of fluoroquinolone prescribing across 3 antimicrobial stewa

180 INTERPRETATION: Restricting fluoroquinolone prescribing appears to explain the decli

181 Our goal was to describe fluoroquinolone prescribing at hospital discharge across

182 /or prospective audit and feedback to target fluoroquinolone prescribing during hospitalization (fluo

183 nolone prescribing were associated with less fluoroquinolone prescribing during hospitalization, but

184 stewardship efforts to minimize and improve fluoroquinolone prescribing should also focus on antimic

185 al-based stewardship interventions targeting fluoroquinolone prescribing were associated with less fl

186 or prospective audit and feedback to target fluoroquinolone prescribing.

187 /or prospective audit and feedback to target fluoroquinolone prescribing.

188 ly in hospitals without a strategy to manage fluoroquinolone prescribing.

189 lf-reported 1 of 3 strategies for optimizing fluoroquinolone prescribing: prospective audit and feedb

190 Our goal was to describe fluoroquinolone-prescribing at hospital discharge across

191 stewardship efforts to minimize and improve fluoroquinolone-prescribing should also focus on antibio

192 Health Administration (VHA) and to contrast fluoroquinolone-prescribing volume and appropriateness a

193 ly in hospitals without a strategy to manage fluoroquinolone-prescribing.

194 -reported one of 3 strategies for optimizing fluoroquinolone-prescribing: prospective audit-and-feedb

195 A large proportion of post-discharge fluoroquinolone prescriptions were inappropriate, especi

196 A large proportion of postdischarge fluoroquinolone prescriptions were inappropriate, especi

197 In fluoroquinolone-prophylaxed patients, Escherichia coli w

198 an within 2 days of starting conditioning or fluoroquinolone prophylaxis and continued until 7 days a

199 e-blind study, subjects undergoing HSCT with fluoroquinolone prophylaxis stratified by transplant typ

200 Fluoroquinolone prophylaxis was associated with decrease

201 fter neutrophil engraftment or completion of fluoroquinolone prophylaxis/clinically-indicated antimic

202 ents who underwent susceptibility testing to fluoroquinolones, proportions of resistance ranged from

203 ta-lactam plus either an aminoglycoside or a fluoroquinolone) protected against detrimental transitio

204 e to multiple protomers, including the known fluoroquinolone protomers and the new finding of cephalo

205 exposed per 1,000 population per quarter for fluoroquinolones; relative -74.0% (-80.3 to -67.9) and a

206 Fluoroquinolones remain some of the more commonly prescr

207 -resistant (cipR) Shigella sonnei from 2010, fluoroquinolones remain the recommended therapy for shig

208 A high level of resistance to fluoroquinolones requires the concurrent presence of at

209 nce of S Typhi exhibiting resistance against fluoroquinolones, requiring the trial to be stopped.

210 ERPRETATION: The rapid expansion of ESBL and fluoroquinolone resistance among common Gram-negative pa

211 was reversal of a previously rising rate of fluoroquinolone resistance and flattening of previously

212 Multiple-drug resistance and emerging fluoroquinolone resistance are of concern.

213 It is intuitive that variation in fluoroquinolone resistance is driven by changes in antim

214 ent, but its efficacy should be evaluated as fluoroquinolone resistance is rapidly increasing.

215 proportion (17.6%) of pre-MDR isolates with fluoroquinolone resistance markers, potentially due to u

216 Here we show that the 3 fluoroquinolone resistance mutations are tightly associa

217 As a result, all 3 fluoroquinolone resistance mutations in GyrA and ParC ha

218 s may improve the accuracy of predicting the fluoroquinolone resistance phenotype.

219 The results indicate that fluoroquinolone resistance reached to 35.4% in C. jejuni

220 h extended spectrum beta-lactamase (ESBL) or fluoroquinolone resistance rose significantly after 2003

221 ion, this clone evolved rapidly and acquired fluoroquinolone resistance through precise stepwise muta

222 Fluoroquinolone resistance was more common among E. coli

223 ) and weaker (Southeast Asia) correlation of fluoroquinolone resistance with rifampin resistance, wit

224 ) and weaker (Southeast Asia) correlation of fluoroquinolone resistance with rifampin resistance.

225 drug resistant (XDR) TB, increased acquired fluoroquinolone resistance, and slower TSCC (125.5 vs 89

226 ns in the gyr genes are known to confer most fluoroquinolone resistance, but knowledge about the effe

227 plicated cystitis and 42.6% Escherichia coli fluoroquinolone resistance.

228 tance to other drugs, and increased acquired fluoroquinolone resistance.

229 tegy was favored in generalized epidemics of fluoroquinolone resistance.

230 Furthermore, fluoroquinolone-resistance in K. pneumoniae clinical iso

231 While all fluoroquinolone resistant (FQ(R)) C. coli isolates exami

232 e reported form India, and the majority were fluoroquinolone resistant and not MDR.

233 d by the fimH64 allele), which was uniformly fluoroquinolone resistant, appeared to emerge in the Uni

234 All except one were fluoroquinolone resistant.

235 scherichia coli represent mainly the nested (fluoroquinolone-resistant [FQR]) H30R and H30Rx subclone

236 ncidence of C difficile infections caused by fluoroquinolone-resistant and fluoroquinolone-susceptibl

237 thromycin-resistant Helicobacter pylori, and fluoroquinolone-resistant Campylobacter spp, Neisseria g

238 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolate

239 190 women and 8835 (29.5%) of 29 915 men had fluoroquinolone-resistant E coli events.

240 d an increased risk of bacteriuria caused by fluoroquinolone-resistant E coli.

241 The prevalence of 3G-C and fluoroquinolone-resistant E. coli was 4% and 10%, respec

242 We report that fluoroquinolone-resistant Escherichia coli are found in

243 We screened 94 fecal fluoroquinolone-resistant Escherichia coli isolates from

244 The recently emerged fluoroquinolone-resistant Escherichia coli sequence type

245 ation or infection of the urinary tract with fluoroquinolone-resistant Escherichia coli.

246 fficile decline was driven by elimination of fluoroquinolone-resistant isolates (approximately 67% of

247 C difficile infections caused by fluoroquinolone-resistant isolates declined in four dist

248 The regions of phylogenies containing fluoroquinolone-resistant isolates were short-branched a

249 rred secondary (transmitted) cases caused by fluoroquinolone-resistant isolates with or without hospi

250 e potential for treatment of the problematic fluoroquinolone-resistant MRSA, VRE, and S. pneumoniae,

251 monoresistance, multidrug resistance (MDR), fluoroquinolone-resistant multidrug resistance, second-l

252 ST1193-H64's temporal prevalence trends as a fluoroquinolone-resistant pathogen and commensal; docume

253 , and gyrA-D87G) led to the emergence of the fluoroquinolone-resistant S. sonnei population around 20

254 volutionary history of the recently emergent fluoroquinolone-resistant S. sonnei.

255 Despite the sporadic detection of fluoroquinolone-resistant Shigella in Asia in the early

256 rom an uropathogenic clonal complex ST14 and fluoroquinolone-resistant ST10.

257 e for resistance to rifampin, isoniazid, and fluoroquinolone, respectively.

258 The importance of fluoroquinolone restriction over infection control was s

259 ncA (pyrazinamide), embB (ethambutol), gyrA (fluoroquinolones), rrs (aminoglycosides), rpsL, rrs and

260 promoter (isoniazid), rpoB (rifampin), gyrA (fluoroquinolones), rrs and eis promoter (kanamycin), and

261 Our results suggest that fluoroquinolones should no longer be used for treatment

262 Use of later-generation fluoroquinolones significantly reduced patient mortality

263 Although fluoroquinolones stabilize double-stranded DNA breaks, t

264 oquinolone stewardship had twice as many new fluoroquinolone starts after discharge as hospitals with

265 occurred after discharge, and hospitals with fluoroquinolone stewardship had twice as many new fluoro

266 After adjustment, fluoroquinolone stewardship was associated with fewer pa

267 uinolone prescribing during hospitalization (fluoroquinolone stewardship).

268 compared between hospitals with and without fluoroquinolone stewardship.

269 gh-efficacy (aminoglycosides, tetracyclines, fluoroquinolones, sulfonamides, and chloramphenicol) and

270 Genotype (multilocus sequence type) and fluoroquinolone susceptibility were determined from whol

271 no change in either group of cases caused by fluoroquinolone-susceptible isolates (p>0.2).

272 ions caused by fluoroquinolone-resistant and fluoroquinolone-susceptible isolates was estimated with

273 cidence rate ratio 0.52, 95% CI 0.48-0.56 vs fluoroquinolone-susceptible isolates: 1.02, 0.97-1.08).

274 Alternatives such as fluoroquinolones, tetracyclines, and sulfonamides are po

275 ein synthesis such as macrolides, along with fluoroquinolones that inhibit DNA replication, have been

276 restricted to patients who had not consumed fluoroquinolones themselves.

277 on prevalence densities were associated with fluoroquinolone, third-generation cephalosporin, macroli

278 However, most (66.6%) fluoroquinolone treatment days occurred after discharge,

279 uinolone (37.1% vs 48.2%; P = .01) and fewer fluoroquinolone treatment days per 1000 patients (2282 v

280 The basis of fluoroquinolone treatment failure for Mycoplasma genital

281 this study shows an association between oral fluoroquinolone use and the risk for uveitis-associated

282 antibiotic use by 13% (P = .018) and reduced fluoroquinolone use by 11% (P = .035).

283 Fluoroquinolone use is associated with increased risk of

284 Whether these strategies impact aggregate fluoroquinolone use is unknown.

285 e found a positive association between total fluoroquinolone use lagged by 1 and 2 months and the pro

286 Current oral fluoroquinolone use was associated with an increased ris

287 Vancomycin and fluoroquinolone use was decreased.

288 ntimicrobial stewardship campaigns to reduce fluoroquinolone use, particularly in the winter when use

289 e, excess antibiotic duration, or suboptimal fluoroquinolone use.

290 ptimal conditions, the detector response for fluoroquinolones was linear in the concentration ranges

291 Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolones were active against 94% and 88% of isol

292 When patients treated with fourth-generation fluoroquinolones were compared with those treated with f

293 Increasing MICs of fluoroquinolones were correlated with unsuccessful treat

294 Post-discharge fluoroquinolones were deemed inappropriate in 154 of 375

295 Postdischarge fluoroquinolones were deemed inappropriate in 154 of 375

296 Fluoroquinolones were more likely to be inappropriate at

297 Fluoroquinolones were more likely to be inappropriate at

298 Fluoroquinolones were only given as part of combination

299 B were treated for greater than 14 days, and fluoroquinolones were the most commonly used empiric ant

300 acto monotherapy with a critical drug class (fluoroquinolones), whereas the latter could exclude larg

301 xacin, one of the most frequently prescribed fluoroquinolone, with high affinity (KD=0.1-56.9 nM).